Los Angeles, CA / February 5, 2018 – Trethera Corporation, a biopharmaceutical company committed to developing novel drugs targeting cellular nucleotide metabolism for the treatment of cancer, today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for TRE-515, a novel, first-in-class inhibitor of deoxycytidine kinase for the treatment of patients with myelodysplastic syndromes (MDS). Under this IND, Trethera plans to initiate a Phase 1 study designed to evaluate the safety, pharmacokinetics, and pharmacodynamics of TRE-515 as well as validate several biomarkers in relapsed and/or refractory MDS patients who have no available alternative therapy.
25 January 2017
Emerging Company Profile: University spinout, Trethera – which recently signed a licensing deal to develop Nanotherapeutics Inc.’s ribonucleotide reductase inhibitor Triapine – believes it is the first company to target cancer nucleotide metabolism through a combination approach.
11601 Wilshire Boulevard
Los Angeles, CA 90025